• Product NameRecombinant Human soluble Fas Receptor/TNFRSF6
• Host SpeciesEscherichia coli.
• Purification> 95 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the cytotoxicity of Jurkat cells is between 10-15 μg/ml in the presence of 2 ng/ml of rHuFas Ligand.
• EndotoxinLess than 1 EU/ug of rHusFasR/TNFRSF6 as determined by LAL method.
• Alternative Names    TNFRSF6, CD95, Apo I, Fas Antigen
• UniprotP25445
• Gene ID355
• Calculated MW Approximately 17.6 kDa, a single non-glycosylated polypeptide chain containing 157 amino acids.
• Target Sequence RLSSKSVNAQ VTDINSKGLE LRKTVTTVET QNLEGLHHDG QFCHKPCPPG ERKARDCTVN GDEPDCVPCQ EGKEYTDKAH FSSKCRRCRL CDEGHGLEVE INCTRTQNTK CRCKPNFFCN STVCEHCDPC TKCEHGIIKE CTLTSNTKCK EEGSRSN
• Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

Fas and Fas Ligand (FasL) belong to the TNF superfamily and are type I and type II transmembrane proteins, respectively. Binding of FasL to Fas triggers apoptosis in Fas-bearing cells. The mechanism of apoptosis involves recruitment of pro-caspase 8 through an adaptor molecule called FADD followed by processing of the pro-enzyme to active forms. These active caspases then cleave various cellular substrates leading to the eventual cell death. sFasR is capable of inhibiting FasL-induced apoptosis by acting as a decoy receptor that serves as a sink for FasL.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting